Foresite Capital recently added the great mind of Dr. Molly He to their able team as a Venture Partner. Remarking on the new development, Foresite Capital’s M.D. and chief executive officer, Jim Tananbaum, excitedly noted that the team was thrilled to welcome the highly valued next-generation sequencing researcher. He further added that Dr. He would be a vital resource to the continually expanding firm following her expertise and impeccable leadership skills. Dr. He noted that she was privileged to join and take part in the evolution of Foresite’s next-generation sequencing.
Dr. He brought Foresite an experience of over 15 years in development and research of genomics and drug development practices. The first couple of years of her research career were in the pharmaceutical field where she focused on cancer and immune diseases. She researched and developed antibody and small molecule drugs for the two. Dr. He then moved to Pacific Biosciences and later Illumina. She was mandated with the role of creating and improving protein reagents for both firms. Her impeccable performance in her roles has been due to solid training that she received at Nankai University and the University of California where she earned a bachelor’s degree in biochemistry and a Ph.D. in protein biophysics respectively. Dr. He owns 20 patents and over 20 published research papers.
Foresite Capital helps up-coming public and private healthcare providers grow their capital. It mainly focuses on healthcare firms with disruptive products. The company is located in San Francisco and also runs an office in New York.http://www.insidermonkey.com/hedge-fund/foresite+capital/740/
About Jim Tananbaum
Jim Tananbaum attended Yale University for his BS and BSEE in mathematics and computer science. Soon after, Jim joined the notable Massachusetts Institute of Technology and pursued a master’s degree in HST information theory. Jim further went to Harvard Medical School and Harvard Business School where he attained his MD and MBA respectively.
Jim Tananbaum co-founded and worked for GelTex in 1991, which was later sold to Genzyme. He moved to Sierra Ventures as a partner where he developed healthcare investment service. Jim co-founded several other ventures, such as Theravance and Prospect Venture Partners. In 2010, he launched Foresite Capital Management, which he currently runs as the CEO.
Follow him on Twitter